{"filing":{"accession_number":"0001493152-26-027202","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027202/form8-k.htm"},"events":[{"id":6911,"run_id":6057,"accession_number":"0001493152-26-027202","anchor_item_number":"1.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement granting worldwide exclusive rights to develop, manufacture, and commercialize products under the MIRA-55 and SKNY-1 programs. The amendment does not materially modify previously disclosed core economic terms, suggesting a restructuring or clarification of existing arrangements.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4461,"accession_number":"0001493152-26-027202","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into an Amended and Restated Exclusive License Agreement granting MIRA worldwide exclusive rights to develop, manufacture, and commercialize products under the MIRA-55 and SKNY-1 programs. While this is a material definitive agreement under Item 1.01, it does not fit cleanly into the M\u0026A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The amendment explicitly states it \"does not materially modify the previously disclosed core economic terms,\" suggesting this is a restructuring or clarification of existing arrangements rather than a new material transaction. Classified as other_material given the ambiguity between a routine license amendment and a potentially material IP licensing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:55.034464+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4462,"accession_number":"0001493152-26-027202","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses execution of a \"License Agreement\" via press release on June 4, 2026, but the Item 7.01 disclosure provides no substantive details about the agreement's terms, counterparty, financial impact, or strategic significance. Without access to Exhibit 99.1, the materiality and specific event type cannot be definitively determined; however, a license agreement execution in the pharmaceutical sector is typically material to investors. Classified as \"other_material\" rather than a more specific category due to insufficient detail in the Item text itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:55.034464+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4461,"accession_number":"0001493152-26-027202","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into an Amended and Restated Exclusive License Agreement granting MIRA worldwide exclusive rights to develop, manufacture, and commercialize products under the MIRA-55 and SKNY-1 programs. While this is a material definitive agreement under Item 1.01, it does not fit cleanly into the M\u0026A taxonomy (which focuses on acquisitions, dispositions, mergers, or changes of control). The amendment explicitly states it \"does not materially modify the previously disclosed core economic terms,\" suggesting this is a restructuring or clarification of existing arrangements rather than a new material transaction. Classified as other_material given the ambiguity between a routine license amendment and a potentially material IP licensing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:55.034464+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-04"},{"id":4462,"accession_number":"0001493152-26-027202","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses execution of a \"License Agreement\" via press release on June 4, 2026, but the Item 7.01 disclosure provides no substantive details about the agreement's terms, counterparty, financial impact, or strategic significance. Without access to Exhibit 99.1, the materiality and specific event type cannot be definitively determined; however, a license agreement execution in the pharmaceutical sector is typically material to investors. Classified as \"other_material\" rather than a more specific category due to insufficient detail in the Item text itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:55.034464+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-04"}]}